Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply.
Saved in:
| Title: | Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply. |
|---|---|
| Authors: | Strand V; Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA., Kalunian KC; University of California, San Diego, La Jolla, CA, USA., Wai Lee K; GMAP, AstraZeneca, Cambridge, UK., Seo C; BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, USA., Abreu G; BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden., Tummala R; BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Al-Mossawi H; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Duncan EA; BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA., Lindholm C; BioPharmaceuticals R&D, AstraZeneca, Gothenburg 43183, Sweden. Electronic address: catharina.lindholm@astrazeneca.com. |
| Source: | The Lancet. Rheumatology [Lancet Rheumatol] 2025 Aug; Vol. 7 (8), pp. e527-e528. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
